Eltrombopag meets Phase II ITP endpoint

GlaxoSmithKline (LSE:GSK; GSK) said the two highest doses of eltrombopag ( SB-497115) met the primary endpoint of proportion of patients with a platelet count of at least 50,000/uL in a Phase II trial...